Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II 177Lu-DOTA-cG250 in advanced clear cell renal cell carcinoma
NL-OMON33866Phase 2Active, not recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Aug 2011
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lutetium Lu 177 girentuximab tetraxetan in renal cell carcinoma (RCC) and clear cell renal cell carcinoma (ccRCC), sponsored by Radboud University Medical Center. Primary endpoint: Clinical efficacy by RECIST. Started Aug 2011; status: active, not recruiting.
02
Drugs
lutetium Lu 177 girentuximab tetraxetan
03
Conditions
renal cell carcinoma (RCC)clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NL-OMON33866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON33866.